For high volume screening applications, the HPV Risk/ QIAscreen assay is also available on a fully automated system as the NeuMoDx HPV Test Strip. The automated workflow on the NeuMoDx™ 96 and 288 Molecular Systems include DNA extraction, PCR amplification, fluorescent detection and result calculation.
The assay – designed on the E7 gene region to avoid false negative results due to integration events of L1 regions – and report HPV16 and HPV18 separately and all 13 other high risk types at clinically relevant infection levels. It performs equally well on cervical screening specimens collected in PreservCyt and SurePath samples.
The NeuMoDx HPV Test strip fulfils the requirements to be used for primary cervical screening.
The analytical and clinical validations are performed according to the International “Meijer” HPV DNA Test Guidelines.
Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening
Key features of the NeuMoDx HPV DNA Test Strip on the NeuMoDx Molecular Systems.
For ordering and pricing information, please contact us at email@example.com